MX2019004782A - Compuestos, proceso de obtencion de los compuestos, composicion farmaceutica, uso de los compuestos y metodo de tratamiento de trastornos psiquiatricos y/o trastornos del sueño. - Google Patents
Compuestos, proceso de obtencion de los compuestos, composicion farmaceutica, uso de los compuestos y metodo de tratamiento de trastornos psiquiatricos y/o trastornos del sueño.Info
- Publication number
- MX2019004782A MX2019004782A MX2019004782A MX2019004782A MX2019004782A MX 2019004782 A MX2019004782 A MX 2019004782A MX 2019004782 A MX2019004782 A MX 2019004782A MX 2019004782 A MX2019004782 A MX 2019004782A MX 2019004782 A MX2019004782 A MX 2019004782A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- disorders
- obtaining
- pharmaceutical composition
- sleep disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se relaciona con nuevos e inventivos compuestos derivados benzimidazólicos farmacológicamente activos, los cuales sorprendentemente poseen elevada afinidad a los receptores MT1 y MT2 de la melatonina y baja afinidad a las enzimas del complejo CYP450, especialmente a la CYP1A2. También se describen nuevas e inventivas rutas de síntesis de estos compuestos, composiciones farmacéuticas que comprenden los mismos y el uso de estos compuestos en el tratamiento de individuos acometidos por trastornos psiquiátricos y/o trastornos del sueño relacionados con estos receptores (especialmente la depresión, la ansiedad y los trastornos del ciclo circadiano), además del proceso de producción de la composición.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR102016024814A BR102016024814A2 (pt) | 2016-10-24 | 2016-10-24 | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
| PCT/BR2017/050320 WO2018076090A1 (en) | 2016-10-24 | 2017-10-23 | Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019004782A true MX2019004782A (es) | 2019-10-09 |
Family
ID=62023150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019004782A MX2019004782A (es) | 2016-10-24 | 2017-10-23 | Compuestos, proceso de obtencion de los compuestos, composicion farmaceutica, uso de los compuestos y metodo de tratamiento de trastornos psiquiatricos y/o trastornos del sueño. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10781182B2 (es) |
| EP (2) | EP3529234B1 (es) |
| JP (1) | JP7194683B2 (es) |
| KR (1) | KR102594251B1 (es) |
| CN (2) | CN115181108A (es) |
| AR (1) | AR109467A1 (es) |
| AU (1) | AU2017351756B2 (es) |
| BR (2) | BR102016024814A2 (es) |
| CA (1) | CA3042040A1 (es) |
| CL (1) | CL2019001105A1 (es) |
| CO (1) | CO2019004756A2 (es) |
| DK (1) | DK3529234T3 (es) |
| EC (1) | ECSP19032963A (es) |
| ES (1) | ES2970546T3 (es) |
| FI (1) | FI3529234T3 (es) |
| MX (1) | MX2019004782A (es) |
| PE (1) | PE20191046A1 (es) |
| PT (1) | PT3529234T (es) |
| SG (2) | SG10202009001TA (es) |
| UY (1) | UY37334A (es) |
| WO (1) | WO2018076090A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109843888B (zh) | 2016-10-24 | 2022-03-01 | 阿斯利康(瑞典)有限公司 | 可用于治疗癌症的6，7，8，9-四氢-3H-吡唑并[4，3-f]异喹啉衍生物 |
| BR102016024814A2 (pt) * | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
| ES2931320T3 (es) | 2017-01-30 | 2022-12-28 | Astrazeneca Ab | Moduladores del receptor de estrógeno |
| AR121842A1 (es) * | 2020-04-15 | 2022-07-13 | Ache Laboratorios Farmaceuticos Sa | Compuesto de benzimidazol para el tratamiento de trastornos metabólicos |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2658818B1 (fr) | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5260051A (en) | 1990-12-17 | 1993-11-09 | Lever Brothers Company, Division Of Conopco, Inc. | Compositions comprising phosphate ester compounds containing a beneficial reagent component |
| FR2674524B1 (fr) | 1991-03-25 | 1993-05-21 | Adir | Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2680366B1 (fr) * | 1991-08-13 | 1995-01-20 | Adir | Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
| GB9326192D0 (en) | 1993-12-22 | 1994-02-23 | Glaxo Group Ltd | Chemical compounds |
| JP3559045B2 (ja) * | 1994-06-10 | 2004-08-25 | ナウチノ−イススレドバテルスキ インスティテュト ファルマコロギイ ロスシイスコイ アカデミイ メディツィンスキフ ナウク | 薬理学的活性を有する２−メルカプトベンズイミダゾール誘導体 |
| US5496826A (en) | 1994-09-02 | 1996-03-05 | Bristol-Myers Squibb Company | Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides |
| FR2738818B1 (fr) | 1995-09-18 | 1997-12-05 | Valentonine | Nouveaux derives d'oxydation d'indolylalkylamines, et leur utilisation a titre de medicament |
| US6034239A (en) * | 1996-03-08 | 2000-03-07 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
| JP2884153B2 (ja) * | 1996-03-08 | 1999-04-19 | 武田薬品工業株式会社 | 三環性化合物、その製造法および剤 |
| HU226524B1 (en) | 1996-12-10 | 2009-03-30 | Bristol Myers Squibb Co | Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane derivatives and the use thereof for producing pharmaceutical compositions having melatonergic activity |
| EP1082115A4 (en) | 1998-06-05 | 2002-10-24 | Bristol Myers Squibb Co | MELATONERGICS BASED ON HETEROCYCLIC CIS DERIVATIVES OF CYCLOPROPANE |
| US6211225B1 (en) | 1999-06-30 | 2001-04-03 | Bristol-Meyers Squibb | Heterocyclic aminopyrrolidine derivatives as melatonergic agents |
| WO2003062224A1 (en) | 2002-01-17 | 2003-07-31 | Eli Lilly And Company | Aza-cyclic compounds as modulators of acetylcholine receptors |
| CA2554774A1 (en) | 2004-02-23 | 2005-09-01 | Dainippon Sumitomo Pharma Co., Ltd. | Novel heterocyclic compound |
| ES2264641B1 (es) * | 2005-06-17 | 2008-03-01 | Quimica Sintetica, S.A. | Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios. |
| WO2008032164A2 (en) * | 2006-09-12 | 2008-03-20 | Pfizer Products Inc. | Benzimidazolone derivatives |
| US20100056515A1 (en) | 2006-10-25 | 2010-03-04 | Kazuyoshi Aso | Benzimidazole compounds |
| RU2401831C2 (ru) * | 2008-12-15 | 2010-10-20 | Алла Хем, Ллс | Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения |
| BR102016024814A2 (pt) * | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
-
2016
- 2016-10-24 BR BR102016024814A patent/BR102016024814A2/pt not_active Application Discontinuation
-
2017
- 2017-07-19 UY UY0001037334A patent/UY37334A/es unknown
- 2017-08-30 AR ARP170102402A patent/AR109467A1/es unknown
- 2017-10-23 CA CA3042040A patent/CA3042040A1/en active Pending
- 2017-10-23 DK DK17865155.0T patent/DK3529234T3/da active
- 2017-10-23 MX MX2019004782A patent/MX2019004782A/es unknown
- 2017-10-23 CN CN202210815568.3A patent/CN115181108A/zh active Pending
- 2017-10-23 PE PE2019000861A patent/PE20191046A1/es unknown
- 2017-10-23 JP JP2019542758A patent/JP7194683B2/ja active Active
- 2017-10-23 AU AU2017351756A patent/AU2017351756B2/en active Active
- 2017-10-23 SG SG10202009001TA patent/SG10202009001TA/en unknown
- 2017-10-23 KR KR1020197011842A patent/KR102594251B1/ko active IP Right Grant
- 2017-10-23 FI FIEP17865155.0T patent/FI3529234T3/fi active
- 2017-10-23 SG SG11201903113TA patent/SG11201903113TA/en unknown
- 2017-10-23 BR BR112019008197A patent/BR112019008197A2/pt active Search and Examination
- 2017-10-23 PT PT178651550T patent/PT3529234T/pt unknown
- 2017-10-23 EP EP17865155.0A patent/EP3529234B1/en active Active
- 2017-10-23 US US16/344,721 patent/US10781182B2/en active Active
- 2017-10-23 CN CN201780079647.XA patent/CN110088092B/zh active Active
- 2017-10-23 WO PCT/BR2017/050320 patent/WO2018076090A1/en active Application Filing
- 2017-10-23 EP EP20185268.8A patent/EP3741760A1/en active Pending
- 2017-10-23 ES ES17865155T patent/ES2970546T3/es active Active
-
2019
- 2019-04-23 CL CL2019001105A patent/CL2019001105A1/es unknown
- 2019-05-09 EC ECSENADI201932963A patent/ECSP19032963A/es unknown
- 2019-05-09 CO CONC2019/0004756A patent/CO2019004756A2/es unknown
-
2020
- 2020-05-13 US US15/930,990 patent/US11091445B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019004782A (es) | Compuestos, proceso de obtencion de los compuestos, composicion farmaceutica, uso de los compuestos y metodo de tratamiento de trastornos psiquiatricos y/o trastornos del sueño. | |
| UA99882C2 (uk) | Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти) | |
| MX353461B (es) | PROCESOS PARA PREPARAR COMPUESTOS ÚTILES COMO INHIBIDORES DE CINASA ATAXIA TELANGIECTASIA MUTADA Y Rad3 RELACIONADOS (ATR). | |
| PH12017500829A1 (en) | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease | |
| EA201071057A1 (ru) | Производные азетидина и циклобутана как ингибиторы jak-киназ | |
| UA108743C2 (uk) | Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази | |
| EA201790246A1 (ru) | Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы | |
| EA201592033A1 (ru) | 3-(2-АМИНОПИРИМИДИН-4-ИЛ)-5-(3-ГИДРОКСИПРОПИНИЛ)-1H-ПИРРОЛО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NIK ДЛЯ ЛЕЧЕНИЯ РАКА | |
| MY160075A (en) | Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
| MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
| EA201791829A1 (ru) | Амидные соединения в качестве агонистов рецептора 5-ht | |
| PH12019500497A1 (en) | Heteroaryl carboxamide compounds as inhibitors of ripk2 | |
| CR20220160A (es) | Derivados de piridazin-3(2h)-ona fusionados con azol | |
| PH12017500595B1 (en) | Aldosterone synthase inhibitors | |
| PH12017500089B1 (en) | Aldosterone synthase inhibitors | |
| MY164998A (en) | Isoquinolinone derivatives as nk3 antagonists | |
| MX2015008733A (es) | Derivados de 1,2,3-triazol-4-amina para el tratamiento de enfermedades y transtornos relacionados con receptores sigma. | |
| NZ720879A (en) | Indazole compounds as 5-ht4 receptor agonists | |
| MX2019014272A (es) | Compuestos policiclicos y usos de los mismos. | |
| MX2018004524A (es) | Derivados de eter ciclico de pirazolo[1,5-a]pirimidin-3-carboxiami da. | |
| CY1110087T1 (el) | Μεθοδοι παρασκευης ενωσεων που περιεχουν πυρραζολιο | |
| MX2019000276A (es) | Nuevos derivados ciclopropílicos. | |
| EA201690240A1 (ru) | Новые соединения индазола и способ их получения | |
| MX2015012393A (es) | Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina. | |
| UA104730C2 (en) | Isoquinolinone derivatives as nk3 antagonists |